Press release Therabel restructuring
Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO) is an innovative company specializing in the development of orphan oncology drugs.
Articles posted on the internet refer to a social restructuring project at Therabel Lucien Pharma laboratory - a subsidiary of the Dutch group Therabel – ONXEO’s (Euronext Paris, Nasdaq, OMX Copenhagen – ONXEO) partner for the commercialization of Loramyc® in Europe.
ONXEO cannot comment on this project at this time and it should be considered that the terms of the agreement remain unchanged.
As ONXEO has focused its growth strategy on medicines treating orphan oncology, Loramyc® is not a strategic product for the company, does not significantly contribute to its revenues nor results, and should not be considered as a significant factor in its valuation.
All information related to Loramyc®, including any change to its distribution channel, will be the subject of a communication in reference documents and semi-annual publications.